Guardant Health Stock Performance
| GH Stock | USD 35.10 0.73 2.12% |
On a scale of 0 to 100, Guardant Health holds a performance score of 11. The company retains a Market Volatility (i.e., Beta) of 1.84, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Guardant Health will likely underperform. Please check Guardant Health's sortino ratio, semi variance, and the relationship between the standard deviation and value at risk , to make a quick decision on whether Guardant Health's current trending patterns will revert.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Guardant Health are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak technical indicators, Guardant Health demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.99 | Five Day Return 12.46 | Year To Date Return 32.23 | Ten Year Return 8.87 | All Time Return 8.87 |
1 | Disposition of tradable shares by Joyce Meghan V. of Guardant Health subject to Rule 16b-3 | 09/04/2024 |
2 | Disposition of 2909 shares by Darya Chudova of Guardant Health subject to Rule 16b-3 | 09/09/2024 |
3 | Dans le cadre de lESMO 2024, Guardant Health prsentera des donnes dmontrant les solides performances de sa technologie doncologie de prcision dans plusieurs typ... | 09/13/2024 |
4 | Disposition of 134 shares by John Saia of Guardant Health at 28.58 subject to Rule 16b-3 | 09/27/2024 |
5 | Disposition of 11461 shares by Helmy Eltoukhy of Guardant Health subject to Rule 16b-3 | 09/30/2024 |
6 | Disposition of 6569 shares by John Saia of Guardant Health subject to Rule 16b-3 | 10/02/2024 |
7 | Guardant Health Inc Stock Price Down 3.84 percent on Oct 17 | 10/17/2024 |
8 | Insider Trading | 10/21/2024 |
9 | Disposition of 154 shares by Krognes Steve E. of Guardant Health subject to Rule 16b-3 | 10/31/2024 |
10 | Unveiling Guardant Health Q3 Outlook Wall Street Estimates for Key Metrics | 11/05/2024 |
11 | Guardant Health, Inc. Q3 2024 Earnings Call Transcript | 11/08/2024 |
12 | Disposition of 8435 shares by Clark Ian T of Guardant Health subject to Rule 16b-3 | 11/12/2024 |
13 | Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 11/13/2024 |
14 | GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates | 11/14/2024 |
15 | Aigen Investment Management LP Increases Stake in Guardant Health, Inc. | 11/15/2024 |
16 | Disposition of 7000 shares by Kumud Kalia of Guardant Health at 29.246 subject to Rule 16b-3 | 11/18/2024 |
17 | Guardant Health Set To Dominate The Growing Liquid Biopsy Market | 11/22/2024 |
18 | Guardant Health Inc Stock Price Down 3.59 percent on Nov 26 | 11/26/2024 |
| Begin Period Cash Flow | 141.9 M |
Guardant |
Guardant Health Relative Risk vs. Return Landscape
If you would invest 2,558 in Guardant Health on August 30, 2024 and sell it today you would earn a total of 952.00 from holding Guardant Health or generate 37.22% return on investment over 90 days. Guardant Health is generating 0.5762% of daily returns and assumes 3.8908% volatility on return distribution over the 90 days horizon. Put differently, 34% of stocks are less risky than Guardant on the basis of their historical return distribution, and some 89% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
Guardant Health Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Guardant Health's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Guardant Health, and traders can use it to determine the average amount a Guardant Health's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1481
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.89 actual daily | 34 66% of assets are more volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Guardant Health is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Guardant Health by adding it to a well-diversified portfolio.
Guardant Health Fundamentals Growth
Guardant Stock prices reflect investors' perceptions of the future prospects and financial health of Guardant Health, and Guardant Health fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Guardant Stock performance.
| Return On Equity | -6.09 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.74) % | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | 4.71 B | ||||
| Shares Outstanding | 123.56 M | ||||
| Price To Earning | (12.01) X | ||||
| Price To Book | 55.67 X | ||||
| Price To Sales | 6.13 X | ||||
| Revenue | 563.95 M | ||||
| Gross Profit | 293.21 M | ||||
| EBITDA | (433.31 M) | ||||
| Net Income | (479.45 M) | ||||
| Cash And Equivalents | 853.69 M | ||||
| Cash Per Share | 8.35 X | ||||
| Total Debt | 1.35 B | ||||
| Debt To Equity | 4.32 % | ||||
| Current Ratio | 6.18 X | ||||
| Book Value Per Share | (0.49) X | ||||
| Cash Flow From Operations | (324.98 M) | ||||
| Earnings Per Share | (4.28) X | ||||
| Market Capitalization | 4.25 B | ||||
| Total Asset | 1.79 B | ||||
| Retained Earnings | (2.14 B) | ||||
| Working Capital | 1.14 B | ||||
| Current Asset | 219.68 M | ||||
| Current Liabilities | 24.24 M | ||||
About Guardant Health Performance
By evaluating Guardant Health's fundamental ratios, stakeholders can gain valuable insights into Guardant Health's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Guardant Health has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Guardant Health has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 99.59 | 68.61 | |
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.36) | (0.38) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (3.02) | (3.17) |
Things to note about Guardant Health performance evaluation
Checking the ongoing alerts about Guardant Health for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Guardant Health help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Guardant Health appears to be risky and price may revert if volatility continues | |
| The company generated the yearly revenue of 563.95 M. Annual Net Loss to common stockholders was (479.45 M) with gross profit of 293.21 M. | |
| Guardant Health reports about 853.69 M in cash with (324.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.35. | |
| Guardant Health has a poor financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Guardant Health Inc Stock Price Down 3.59 percent on Nov 26 |
- Analyzing Guardant Health's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Guardant Health's stock is overvalued or undervalued compared to its peers.
- Examining Guardant Health's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Guardant Health's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Guardant Health's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Guardant Health's stock. These opinions can provide insight into Guardant Health's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Guardant Stock analysis
When running Guardant Health's price analysis, check to measure Guardant Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guardant Health is operating at the current time. Most of Guardant Health's value examination focuses on studying past and present price action to predict the probability of Guardant Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guardant Health's price. Additionally, you may evaluate how the addition of Guardant Health to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |